AGL:LSE-ANGLE plc (GBX)

COMMON STOCK | Diagnostics & Research | LSE

Last Closing Price

GBX 98.00

Change

+14.80 (+17.79)%

Market Cap

GBX 0.21B

Volume

2.21M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products. It develops and commercializes Parsortix cell separation system, which captures and harvests circulating tumor cells in cancer patient blood; and Ziplex multiplex analysis system that is used with the ovarian cancer clinical application. The company was founded in 1994 and is based in Guildford, the United Kingdom. Address: Surrey Research Park, Guildford, United Kingdom, GU2 7AF

Company Website : http://www.angleplc.com

Address : Surrey Research Park, Guildford, United Kingdom, GU2 7AF

Fiscal Year End : April

Currency: GBX

Country : UK

Technical Indicators

Beta : 0.75

52 Week High : 97.93

52 Week Low : 39.00

200 Day Moving Average : 62.68

50 Day Moving Average : 81.57

Shares Held By Insiders : 128.82%

Shares Held by Institutions : 26.05%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-16 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MXCT:LSE MaxCyte, Inc

-10.00 (-1.16%)

 GBX0.81B N/A N/A
MXCL:LSE MaxCyte, Inc

N/A

 GBX0.81B N/A N/A
IDHC:LSE Integrated Diagnostics Holding..

N/A

 GBX0.71B 7.08 0.72
RENX:LSE Renalytix AI plc

+16.00 (+1.73%)

 GBX0.67B N/A N/A
EKF:LSE EKF Diagnostics Holdings plc

+0.60 (+0.76%)

 GBX0.36B 33.08 16.57
HZD:LSE Horizon Discovery Group plc

N/A

 GBX0.30B N/A N/A
NCYT:LSE Novacyt S.A

-8.50 (-2.07%)

 GBX0.28B 7.74 5.99
ABDX:LSE Abingdon Health Plc

N/A

 GBX0.08B N/A 257.80
GDR:LSE genedrive plc

-3.00 (-4.29%)

 GBX0.04B N/A N/A
PRM:LSE Proteome Sciences plc

N/A

 GBX0.01B 50.25 33.08

ETFs Containing AGL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 105.24% 100% A+ 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 105.24% 100% A+ 98% A+
Trailing 12 Months  
Capital Gain 81.48% 67% D+ 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 81.48% 67% D+ 82% B-
Trailing 5 Years  
Capital Gain 34.25% 71% C- 53% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.25% 57% F 49% F
Average Annual (5 Year Horizon)  
Capital Gain 4.14% 44% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.14% 33% F 42% F
Risk Return Profile  
Volatility (Standard Deviation) 31.37% 100% A+ 37% F
Risk Adjusted Return 13.20% 33% F 37% F
Market Capitalization 0.21B 36% F 54% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 7.02 50% F 13% F
Price / Cash Flow Ratio -20.11 64% D 82% B-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 22.99% 91% A- 92% A-
Return on Assets -24.24% 20% F 7% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.75 60% D- 71% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector